180 related articles for article (PubMed ID: 36497264)
1. Canonical WNT Signaling Activated by WNT7B Contributes to L-HBs-Mediated Sorafenib Resistance in Hepatocellular Carcinoma by Inhibiting Mitophagy.
Liu LJ; Lv Z; Xue X; Xing ZY; Zhu F
Cancers (Basel); 2022 Nov; 14(23):. PubMed ID: 36497264
[TBL] [Abstract][Full Text] [Related]
2. HBV Enhances Sorafenib Resistance in Hepatocellular Carcinoma by Reducing Ferroptosis via SRSF2-Mediated Abnormal PCLAF Splicing.
Liu L; Lv Z; Wang M; Zhang D; Liu D; Zhu F
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834680
[TBL] [Abstract][Full Text] [Related]
3. Hepatic expression of oncogenes Bmi1 and Dkk1 is up-regulated in hepatitis B virus surface antigen-transgenic mice and can be induced by treatment with HBV particles or lipopolysaccharides in vitro.
Zhang R; Real CI; Liu C; Baba HA; Gerken G; Lu M; Broering R
Int J Cancer; 2017 Jul; 141(2):354-363. PubMed ID: 28419472
[TBL] [Abstract][Full Text] [Related]
4. An Increase in the Levels of Middle Surface Antigen Characterizes Patients Developing HBV-Driven Liver Cancer Despite Prolonged Virological Suppression.
Brancaccio G; Salpini R; Piermatteo L; Surdo M; Fini V; Colagrossi L; Cantone M; Battisti A; Oda Y; Di Carlo D; Ceccherini-Silberstein F; Perno CF; Gaeta GB; Svicher V
Microorganisms; 2021 Apr; 9(4):. PubMed ID: 33918474
[TBL] [Abstract][Full Text] [Related]
5. Association of concurrent hepatitis B surface antigen and antibody to hepatitis B surface antigen with hepatocellular carcinoma in chronic hepatitis B virus infection.
Jang JS; Kim HS; Kim HJ; Shin WG; Kim KH; Lee JH; Kim HY; Kim DJ; Lee MS; Park CK; Jeong BH; Kim YS; Jang MK
J Med Virol; 2009 Sep; 81(9):1531-8. PubMed ID: 19623669
[TBL] [Abstract][Full Text] [Related]
6. Restoration of miR-193b sensitizes Hepatitis B virus-associated hepatocellular carcinoma to sorafenib.
Mao K; Zhang J; He C; Xu K; Liu J; Sun J; Wu G; Tan C; Zeng Y; Wang J; Xiao Z
Cancer Lett; 2014 Oct; 352(2):245-52. PubMed ID: 25034398
[TBL] [Abstract][Full Text] [Related]
7. HBsAg-negative hepatitis B virus infections in hepatitis C virus-associated hepatocellular carcinoma.
Momosaki S; Nakashima Y; Kojiro M; Tabor E
J Viral Hepat; 2005 May; 12(3):325-9. PubMed ID: 15850475
[TBL] [Abstract][Full Text] [Related]
8. Cripto-1 contributes to stemness in hepatocellular carcinoma by stabilizing Dishevelled-3 and activating Wnt/β-catenin pathway.
Lo RC; Leung CO; Chan KK; Ho DW; Wong CM; Lee TK; Ng IO
Cell Death Differ; 2018 Aug; 25(8):1426-1441. PubMed ID: 29445127
[TBL] [Abstract][Full Text] [Related]
9. Interplay of Wnt β-catenin pathway and miRNAs in HBV pathogenesis leading to HCC.
Rana MA; Ijaz B; Daud M; Tariq S; Nadeem T; Husnain T
Clin Res Hepatol Gastroenterol; 2019 Aug; 43(4):373-386. PubMed ID: 30377095
[TBL] [Abstract][Full Text] [Related]
10. Sorafenib use in hepatitis B virus- or hepatitis C virus-related hepatocellular carcinoma: A propensity score matching study.
Lee YC; Wang JH; Chen CH; Hung CH; Lo KC; Yen YH; Kee KM; Hu TH; Lu SN; Kuo YH
Kaohsiung J Med Sci; 2021 Oct; 37(10):894-902. PubMed ID: 34166565
[TBL] [Abstract][Full Text] [Related]
11. CCL22 signaling contributes to sorafenib resistance in hepatitis B virus-associated hepatocellular carcinoma.
Gao Y; Fan X; Li N; Du C; Yang B; Qin W; Fu J; Markowitz GJ; Wang H; Ma J; Cheng S; Yang P
Pharmacol Res; 2020 Jul; 157():104800. PubMed ID: 32278046
[TBL] [Abstract][Full Text] [Related]
12. Coexistence of hepatitis B surface antigen and antibody to hepatitis B surface may increase the risk of hepatocellular carcinoma in chronic hepatitis B virus infection: a retrospective cohort study.
Seo SI; Choi HS; Choi BY; Kim HS; Kim HY; Jang MK
J Med Virol; 2014 Jan; 86(1):124-30. PubMed ID: 24127328
[TBL] [Abstract][Full Text] [Related]
13. Functional interaction between Wnt3 and Frizzled-7 leads to activation of the Wnt/beta-catenin signaling pathway in hepatocellular carcinoma cells.
Kim M; Lee HC; Tsedensodnom O; Hartley R; Lim YS; Yu E; Merle P; Wands JR
J Hepatol; 2008 May; 48(5):780-91. PubMed ID: 18313787
[TBL] [Abstract][Full Text] [Related]
14. Genetic polymorphisms in the Wnt/β-catenin pathway genes as predictors of tumor development and survival in patients with hepatitis B virus-associated hepatocellular carcinoma.
Kim SS; Cho HJ; Lee HY; Park JH; Noh CK; Shin SJ; Lee KM; Yoo BM; Lee KJ; Cho SW; Cheong JY
Clin Biochem; 2016 Jul; 49(10-11):792-801. PubMed ID: 26968103
[TBL] [Abstract][Full Text] [Related]
15. Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation.
Faria LC; Gigou M; Roque-Afonso AM; Sebagh M; Roche B; Fallot G; Ferrari TC; Guettier C; Dussaix E; Castaing D; Brechot C; Samuel D
Gastroenterology; 2008 Jun; 134(7):1890-9; quiz 2155. PubMed ID: 18424269
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis B Virus Small Envelope Protein Promotes Hepatocellular Carcinoma Angiogenesis via Endoplasmic Reticulum Stress Signaling To Upregulate the Expression of Vascular Endothelial Growth Factor A.
Wu SX; Ye SS; Hong YX; Chen Y; Wang B; Lin XJ; Lin X
J Virol; 2022 Feb; 96(4):e0197521. PubMed ID: 34910612
[TBL] [Abstract][Full Text] [Related]
17. Coexistence of low levels of HBsAg and high levels of anti-HBs may increase risk of hepatocellular carcinoma in chronic hepatitis B patients with high HBV load.
Jin ZZ; Jin FF; Liu X; Liu N; Wen F; Lou JL
Braz J Infect Dis; 2019; 23(5):343-351. PubMed ID: 31542378
[TBL] [Abstract][Full Text] [Related]
18. Natural Killer Cell-Derived Interferon-Gamma Promotes Hepatocellular Carcinoma Through the Epithelial Cell Adhesion Molecule-Epithelial-to-Mesenchymal Transition Axis in Hepatitis B Virus Transgenic Mice.
Chen Y; Hao X; Sun R; Wei H; Tian Z
Hepatology; 2019 Apr; 69(4):1735-1750. PubMed ID: 30329167
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive analyses of mutations and hepatitis B virus integration in hepatocellular carcinoma with clinicopathological features.
Kawai-Kitahata F; Asahina Y; Tanaka S; Kakinuma S; Murakawa M; Nitta S; Watanabe T; Otani S; Taniguchi M; Goto F; Nagata H; Kaneko S; Tasaka-Fujita M; Nishimura-Sakurai Y; Azuma S; Itsui Y; Nakagawa M; Tanabe M; Takano S; Fukasawa M; Sakamoto M; Maekawa S; Enomoto N; Watanabe M
J Gastroenterol; 2016 May; 51(5):473-86. PubMed ID: 26553052
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic silencing of SFRP1 and SFRP5 by hepatitis B virus X protein enhances hepatoma cell tumorigenicity through Wnt signaling pathway.
Xie Q; Chen L; Shan X; Shan X; Tang J; Zhou F; Chen Q; Quan H; Nie D; Zhang W; Huang AL; Tang N
Int J Cancer; 2014 Aug; 135(3):635-46. PubMed ID: 24374650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
